本周，A股回调，板块题材上，创新药、CRO、影视院线等板块涨幅居前，小金属、煤炭、稀土永磁等 板块跌幅居前。在指数方面，沪深300指数下跌1.8%，中证A500指数下跌1.6%，创业板指数下跌 0.7%，上证科创板50成份指数下跌1.7%。 虽然市场略有调整，但是融资客继续大幅加仓A股，全周合计融资净买入372亿元，连续第6周净买入超 百亿元。融资余额达1.97万亿元，创2015年6月以来10年新高。绝大部分申万一级行业获得融资净买 入，其中医药生物、电子两行业均获得超60亿元净买入，计算机行业获得逾30亿元净买入，银行、通信 两行业也获得超20亿元净买入。仅煤炭、石油石化、有色金属、农林牧渔等行业融资资金小幅净卖出。 回顾刚刚过去的7月，在创新药板块亮眼行情下，康辰药业、博瑞医药、康方生物等金股领涨。具体来 看，由平安证券推荐的康辰药业以107%的月涨幅成为当月最牛金股；由东吴证券推荐的博瑞医药以 82%的月涨幅排名第二；排名第三的是港股的康方生物，7月涨幅为68%，由东北证券推荐；平安证券 推荐的苑东生物则以57%的月涨幅排名第四。 电子及通信板块也有一些金股7月涨幅亮眼。例如，在电子板块中，长江证券推荐 ...

（原标题：7月金股战绩：最牛暴涨107%！8月金股出炉，这只人气最高） 进入8月，券商最新一期金股名单陆续出炉，电子、基础化工、医药生物、机械设备等行业金股数量占比靠前。机构普遍看好市场冲击新高，东方 财富、洛阳钼业成为本月机构关注度最高的金股。 回顾刚刚过去的7月份，创新药板块亮眼行情下，康辰药业、博瑞医药、康方生物等金股领涨，其中康辰药业以107%的月涨幅成为最牛金股。 7月金股最牛上涨107% 回顾7月金股表现，医药生物、电子、通信行业的金股涨幅居前。 机构：市场或冲击新高 每市APP显示，7月份，创新药板块牛冠股市，该月金股涨幅前四均为医药股。具体来看，由平安证券推荐的康辰药业以107%的月涨幅成为当月 最牛金股；由东吴证券推荐的博瑞医药以82%的月涨幅排名第二；排名第三的是港股的康方生物，7月涨幅为68%，由东北证券推荐；平安证券推 荐的苑东生物则以57%的月涨幅排名第四。 电子及通信板块也有一些金股7月涨幅亮眼。例如，电子板块中，长江证券推荐的东山精密7月份上涨了55%，东兴证券推荐的统联精密7月上涨 50%；通信板块中，多家券商看好的中际旭创、新易盛7月均上涨约49%。 从各家券商7月金股组合月 ...

Group 1 - Over 180 A-shares and Hong Kong stocks have been included in the brokerage "golden stock" list for August, with Dongfang Zhihao being the most recommended stock by six brokerages [1][2] - The stocks with high attention include Dongpeng Beverage, Daikin Heavy Industries, Wanhua Chemical, Huadian Technology, and Luoyang Molybdenum [1][2] - The brokerage "golden stock" index for July showed that over 63% of the recommended stocks achieved positive returns, with Kangchen Pharmaceutical leading with a 106.74% increase [2][3] Group 2 - The market outlook for A-shares suggests a potential oscillating consolidation phase, benefiting growth stocks due to a weak dollar environment [1][4] - Analysts expect the A-share market to experience a gradual rise in index with increased volatility, influenced by policy expectations and economic recovery [4] - Key investment focuses include consumption sectors, technology (AI, robotics, semiconductors), dividend stocks, and gold [4] Group 3 - In the Hong Kong market, stocks like CNOOC, Pop Mart, and China Hongqiao are viewed positively by brokerages, with China Hongqiao reaching a historical high in stock price [2][4] - The overall performance of the Hong Kong market in July showed an upward trend, with expectations for continued growth in August due to stable domestic growth policies [4]

Group 1 - In August, a total of 178 stocks were recommended by brokerages, with Dongfang Caifu being the most recommended stock, receiving endorsements from 6 brokerages [1] - The market showed a positive trend in July, with the Shanghai Composite Index rising by 3.74%, and 279 stocks were recommended, of which 177 saw price increases [2] - Six stocks performed exceptionally well in July, with price increases exceeding 50%, led by Kangchen Pharmaceutical with a 106.74% rise [2] Group 2 - The brokerage stock combination index reflects the professional strength of brokerage research, with 39 indices rising in July, and the Kaiyuan Securities stock index leading with a 15.07% increase [3] - The recommended stocks in August are concentrated in the materials and information technology sectors, each with 45 stocks, while industrial stocks number 31 [4] - Analysts expect a continued strong market in August, emphasizing the importance of the "anti-involution" policy for future corporate profit improvements [4] Group 3 - Key investment themes include growth technology sectors such as AI, robotics, and military, as well as sectors with strong performance support like rare earths and precious metals [5] - Upstream resource products benefiting from increased overseas demand and domestic "anti-involution" policies are also highlighted, including copper, aluminum, and oil [5]

Group 1 - The company announced the approval of the resolution to remove Mr. Peng Long from the position of independent director during the first extraordinary general meeting of shareholders in 2025 [2] - The company also approved the resolution to elect a new independent director for the fourth board of directors [2]

证券代码：688513 证券简称：苑东生物 公告编号：2025-054 成都苑东生物制药股份有限公司 注：计算出席会议的股东（普通股股东）所持有的表决权数量占公司表决权数量的比例已剔 除本次股权登记日登记在册的公司股票回购专户所持有的股份。 （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长王颖女士主持，会议采用现场投票和网 络投票相结合的表决方式。本次股东大会的召集和召开程序、出席会议人员的资 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 8 月 1 日 （二） 股东大会召开的地点：四川省成都市双流区安康路 8 号，苑东生物 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 69 | | --- | --- | | 普通股股东人数 ...

植德京(会)字[2025]0104 号 北京植德律师事务所 关于成都苑东生物制药股份有限公司 2025 年第一次临时股东大会的 法律意见书 二〇二五年八月 北京市东城区东直门南大街 1 号来福士中心办公楼 12 层 邮编：100007 12th Floor, Raffles City Beijing Office Tower, No.1 Dongzhimen South Street, Dongcheng District, Beijing 100007 P.R.C 电话(Tel)：010-56500900 传真(Fax)：010-56500999 www.meritsandtree.com 北京植德律师事务所 关于成都苑东生物制药股份有限公司 2025 年第一次临时股东大会的 法律意见书 植德京(会)字[2025]0104 号 致：成都苑东生物制药股份有限公司（贵公司） 北京植德律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出 席并见证贵公司 2025 年第一次临时股东大会（以下简称"本次会议"）。 本所律师参加本次会议进行见证，并根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人 ...

Core Viewpoint - The article highlights the strong performance of brokerage "gold stocks" in July, with all 30 brokerage gold stock combinations showing positive returns, indicating a robust recovery in the A-share market [2][9]. Brokerage Performance - Ping An Securities' gold stock combination achieved the highest return of 16.57% in July, followed by Kaiyuan Securities at 13.57% and Caitong Securities at 12.93% [3][9][10]. - Notably, all brokerage gold stock combinations recorded positive returns, with several brokerages, including China Merchants Securities and Galaxy Securities, also exceeding 10% returns [9][10]. Top Performing Stocks - The best-performing stock was Kangchen Pharmaceutical, recommended by Ping An Securities, which surged by 106.74% in July [4][6]. - Other notable stocks included Borui Pharmaceutical (82.05%), Kangfang Biotech (68.13%), and Yuandong Biotech (56.60%), all showing significant monthly gains [6][7]. August Strategy - Brokerages are adopting an aggressive strategy for August, focusing on technology growth stocks and cyclical stocks benefiting from mid-year performance reports [12][15]. - The market outlook is optimistic, driven by expectations of recovering corporate ROE and a favorable policy environment, suggesting a continued upward trend in A-shares [15]. Common Recommendations - Several stocks received multiple recommendations from brokerages for August, including Dongfang Caifu, Muyuan Foods, and Wanhua Chemical, each recommended by four different brokerages [16][19]. - The rationale for recommending Dongfang Caifu includes the potential for the securities sector to enter a main upward trend, while Muyuan Foods is recognized for its leading position in the pig farming industry [16][19].

Group 1 - The core viewpoint highlights the active trading and significant growth of the Science and Technology Innovation (Sci-Tech) Pharmaceutical ETF managed by Harvest, with a turnover rate of 21.72% and a transaction volume of 47.63 million yuan on July 31 [2] - Over the past week, the Sci-Tech Pharmaceutical ETF has seen an average daily transaction volume of 53.21 million yuan, ranking first among comparable funds [2] - The fund's scale increased by 16.78 million yuan in the past week, also leading among comparable funds, with a share increase of 12.50 million shares [2] Group 2 - The fund has attracted a total of 14.72 million yuan in inflows over the last five trading days [2] - As of July 31, the net value of the Sci-Tech Pharmaceutical ETF has risen by 48.77% over the past year, ranking 350 out of 2943 in the index stock fund category, placing it in the top 11.89% [2] - The fund's highest monthly return since inception was 23.29%, with the longest consecutive monthly gain being six months and a maximum increase of 41.76% [2] Group 3 - The top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index account for 49.14% of the index, with leading companies including United Imaging Healthcare and BeiGene [2] - The stock performance of the top ten companies shows mixed results, with some stocks experiencing slight declines while others have positive growth [4] Group 4 - The National Healthcare Security Administration has established a "new drug first launch price mechanism" to encourage drug research and innovation, marking a significant policy development [4] - The pharmaceutical and biotech sectors are expected to benefit from a high level of innovation and a potential revaluation of value stocks, with recommendations for companies in the Pharma and Biopharma/Biotech sectors [5] - The medical device industry is also anticipated to benefit from policy optimizations, with recent statements from relevant authorities supporting innovation and addressing issues of internal competition [5]

Group 1 - The report highlights that the "anti-involution" trend is driving a super cycle in commodities, particularly benefiting upstream resources and midstream materials, with the true focus being on the midstream sector [2][14] - The report suggests that the "anti-involution" phenomenon is a precursor to debt reduction, indicating that future demand-side policies will be crucial following the recent supply-side adjustments [3][15] - The ROIC-WACC metric is identified as a key indicator for measuring "involution," with industries like coking coal and photovoltaic equipment being classified as "true involution" sectors that are poised for growth [4][16] Group 2 - The report recommends a stock portfolio for August 2025, including companies such as Dingjie Zhizhi (computing), Yuandong Biological (pharmaceuticals), and BYD (automotive), among others [6][11] - The report emphasizes the importance of monitoring demand-side policy implementation and potential liquidity pressures from overseas markets [5][13] - The report notes that the strong exchange rate is expected to support continued export strength, which may exceed market expectations [5][13]